DURECT Corporation Presenting at the CIBC Biotechnology & Specialty Pharmaceuticals Conference

Download PDF:

CUPERTINO, Calif., April 9, 2007 /PRNewswire-FirstCall via COMTEX News Network/ — DURECT Corporation
(Nasdaq: DRRX) announced today that it will present at the CIBC Biotechnology
& Specialty Pharmaceuticals Conference being held at the Millenium Broadway
Hotel in New York City. Matthew J. Hogan, Chief Financial Officer, will be
presenting at the conference on April 11 at 12:45 p.m. Eastern Time.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020717/DRRXLOGO)

A live audio webcast of the presentation will be available by accessing
DURECT’s homepage at http://www.www.durect.com and clicking “Investor Relations.”

DURECT Corporation is an emerging specialty pharmaceutical company
developing pharmaceutical systems based on its proprietary drug delivery
platform technologies. The Company currently has a number of late-stage
pharmaceutical products in development addressing large markets in pain
management, with a number of research programs underway targeting chronic
disease and other therapeutic areas. For more information, please visit


Matthew J. Hogan, Chief Financial Officer of DURECT Corporation, +1-408-777-4936; or
Jeremiah Hall, Senior Vice President of Feinstein Kean Healthcare, +1-415-677-2700,
jeremiah.hall@fkhealth.com, for DURECT Corporation


Scroll to Top